Connection

Co-Authors

This is a "connection" page, showing publications co-authored by LAN PHAM and KEN HE YOUNG.
Connection Strength

0.992
  1. B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma. Blood. 2018 10 25; 132(17):1805-1817.
    View in: PubMed
    Score: 0.162
  2. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clin Cancer Res. 2018 08 15; 24(16):3967-3980.
    View in: PubMed
    Score: 0.157
  3. Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. Oncotarget. 2018 Jan 02; 9(1):346-360.
    View in: PubMed
    Score: 0.150
  4. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma. Oncotarget. 2016 Dec 06; 7(49):80599-80611.
    View in: PubMed
    Score: 0.143
  5. Targetable vulnerability of deregulated FOXM1/PLK1 signaling axis in diffuse large B cell lymphoma. Am J Cancer Res. 2022; 12(10):4666-4679.
    View in: PubMed
    Score: 0.054
  6. CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 Rearrangements. Front Oncol. 2021; 11:618908.
    View in: PubMed
    Score: 0.048
  7. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Mol Cancer Res. 2021 02; 19(2):249-260.
    View in: PubMed
    Score: 0.047
  8. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol. 2020 11 04; 13(1):148.
    View in: PubMed
    Score: 0.047
  9. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunol Res. 2019 04; 7(4):644-657.
    View in: PubMed
    Score: 0.042
  10. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. Am J Pathol. 2017 Aug; 187(8):1700-1716.
    View in: PubMed
    Score: 0.037
  11. Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients. Am J Surg Pathol. 2017 Feb; 41(2):216-224.
    View in: PubMed
    Score: 0.036
  12. RelA NF-?B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. Aging (Albany NY). 2016 12 08; 8(12):3321-3340.
    View in: PubMed
    Score: 0.036
  13. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget. 2015 Sep 15; 6(27):23157-80.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.